MétaCan
Menu
Back to cohort
Record W4388630440 · doi:10.1002/pd.6460

Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current developments and promising future prospects

2023· review· en· W4388630440 on OpenAlexaff
Akos Herzeg, Beltran Borges, Billie R. Lianoglou, Juan Gonzalez‐Velez, Emma Canepa, Dane Munar, Sarah P. Young, Deeksha Bali, Michel H. Gelb, Pranesh Chakraborty, Priya S. Kishnani, Paul Harmatz, Jennifer L. Cohen, Tippi C. MacKenzie

Bibliographic record

VenuePrenatal Diagnosis · 2023
Typereview
Languageen
FieldMedicine
TopicLysosomal Storage Disorders Research
Canadian institutionsChildren's Hospital of Eastern OntarioUniversity of Ottawa
FundersSanofi GenzymeNational Institutes of HealthSangamo TherapeuticsInventiva PharmaNational Institute for Health and Care ResearchAmicus TherapeuticsUniversity of California, San FranciscoSwedish Orphan BiovitrumBioMarin PharmaceuticalAlexion PharmaceuticalsUltragenyx PharmaceuticalNIH Clinical CenterMaze TherapeuticsEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentSanofi
KeywordsEnzyme replacement therapyIn uteroMedicineImmune systemLysosomal storage diseaseDiseaseSubstrate reduction therapyLysosomal storage disordersFetusBioinformaticsImmunologyNeurosciencePregnancyInternal medicineBiology

Abstract

fetched live from OpenAlex

Lysosomal storage disorders (LSDs) are a group of monogenic condition, with many characterized by an enzyme deficiency leading to the accumulation of an undegraded substrate within the lysosomes. For those LSDs, postnatal enzyme replacement therapy (ERT) represents the standard of care, but this treatment has limitations when administered only postnatally because, at that point, prenatal disease sequelae may be irreversible. Furthermore, most forms of ERT, specifically those administered systemically, are currently unable to access certain tissues, such as the central nervous system (CNS), and furthermore, may initiate an immune response. In utero enzyme replacement therapy (IUERT) is a novel approach to address these challenges evaluated in a first-in-human clinical trial for IUERT in LSDs (NCT04532047). IUERT has numerous advantages: in-utero intervention may prevent early pathology; the CNS can be accessed before the blood-brain barrier forms; and the unique fetal immune system enables exposure to new proteins with the potential to prevent an immune response and may induce sustained tolerance. However, there are challenges and limitations for any fetal procedure that involves two patients. This article reviews the current state of IUERT for LSDs, including its advantages, limitations, and potential future directions for definitive therapies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.004
Threshold uncertainty score0.013

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.063
GPT teacher head0.374
Teacher spread0.310 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations23
Published2023
Admission routes1
Has abstractyes

Explore more

Same venuePrenatal DiagnosisSame topicLysosomal Storage Disorders ResearchFrench-language works237,207